Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

Kim, Sun Bean; Ryoo, Seungeun; Huh, Kyungmin; Joo, Eun Jeong; Kim, Youn Jeong; Choi, Won Suk; Kim, Yae Jean; Yoon, Young Kyung; Heo, Jung Yeon; Seo, Yu Bin; Jeong, Su Jin; Park, Dong Ah; Yu, Su-Yeon; Lee, Hyeon Jeong; Kim, Jimin; Jin, Yan; Park, Jungeun; Peck, Kyong Ran; Choi, Miyoung; Yeom, Joon Sup

doi:10.3947/ic.2021.0303

Cited by 24 publications

(22 citation statements)

References 177 publications

(186 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment was provided in accordance with the revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency guidelines on the treatment of patients with COVID-19 [ 21 ]. Remdesivir was administered to patients who required supplemental oxygen but no invasive ventilation or extracorporeal membrane oxygenation.…”

Section: Methodsmentioning

confidence: 99%

Impact of prior vaccination on clinical outcomes of patients with COVID-19

Seo

Kang

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

Fully vaccinated people remain at risk of Coronavirus Disease 2019 (COVID-19). We examined association between prior vaccination and clinical outcomes in patients with COVID-19. Overall, 387 patients with mild-to-severe COVID-19 were enrolled. Patients were considered fully vaccinated at least 14, 7, and 14 days after receiving the second dose of ChAdOx1 nCoV-19 or mRNA-1273, second dose of BNT162b2, or single dose of Ad26.COV2.S, respectively. The primary outcomes (risk of pneumonia, requirement of supplemental oxygen, and progression to respiratory failure) were compared between vaccinated and unvaccinated patients. Logistic regression analysis was performed to identify factors associated with the outcomes. There were 204 and 183 patients in the vaccinated and unvaccinated groups, respectively. The vaccinated group was significantly older and had more comorbidities than the unvaccinated group. Patients in the unvaccinated group were significantly more likely to develop pneumonia (65.6% vs. 36.8%) or require supplemental oxygen (29.0 vs. 15.7%) than the vaccinated group. The vaccinated group had a significantly shorter time from symptom onset to hospital discharge than the unvaccinated group (10 vs. 11 days; p <0.001). The proportion of patients who progressed to respiratory failure did not differ significantly between groups. In multivariable analyses, vaccination was associated with an approximately 70% and 82% lower likelihood of pneumonia and supplemental oxygen requirement, respectively. Being vaccinated was associated with a significantly lower risk of pneumonia and severe disease when breakthrough infection developed. Our findings support continuous efforts to increase vaccine coverage in populations.

show abstract

Section: Methodsmentioning

confidence: 99%

Impact of prior vaccination on clinical outcomes of patients with COVID-19

Seo

Kang

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

“…No drugs had been approved in Korea for treating mild-to-moderate COVID-19 until the conditional approval of regdanvimab. 23 Therefore, regdanvimab is presently the only agent available in Korea that could prevent progression in patients at high-risk mild-to-moderate COVID-19. However, since the results of the phase 3 clinical trial have not yet been published and accumulated data are scant, the basis for judgment regarding treatment selection in routine clinical practice is insufficient.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study

Park

Kim

et al. 2022

J Korean Med Sci

View full text Add to dashboard Cite

Background Regdanvimab has decreased the time to clinical recovery from coronavirus disease 2019 (COVID-19) and lowered the rate of oxygen therapy according to the results from phase 2/3 randomized controlled trial. More information is needed about the effects and safety of regdanvimab. Methods We analyzed data for patients with high-risk mild or moderate COVID-19 being admitted to Busan Medical Center between December 1, 2020 and April 16, 2021. A propensity score (PS) matched analysis was conducted to compare patients treated with and without regdanvimab. The primary outcome was in-hospital death or disease aggravation which means the need for oxygen therapy (low- or high-flow oxygen therapy and mechanical ventilation) and secondary outcomes comprised the length of hospital stay and adverse reactions. Results Among 1,617 selected patients, 970 (60.0%) were indicated for regdanvimab. Of these, 377 (38.9%) were administered with regdanvimab. Among a 1:1 PS-matched cohort of 377 patients each treated with and without regdanvimab, 19 (5%) and 81 (21.5%) reached the composite outcome of death, or disease aggravation, respectively (absolute risk difference, −16.4%; 95% confidence interval [CI], −21.1, −11.7; relative risk difference, 76.5%; P < 0.001). Regdanvimab significantly reduced the composite outcome of death, or disease aggravation in univariate (odds ratio [OR], 0.194; 95% CI, 0.112–0.320; P < 0.001) and multivariable-adjusted analyses (OR, 0.169; 95% CI, 0.095–0.289; P < 0.001). The hospital stay was shorter for the group with than without regdanvimab. Some hematological adverse reactions were more frequent in the group without regdanvimab, but other adverse reactions did not significantly differ between the groups. Conclusion Regdanvimab was associated with a significantly lower risk of disease aggravation without increasing adverse reactions.

show abstract

“…Based on this, bamlanivimab (LY-CoV555 and LY3819253, Eli Lily and Company, Indianapolis, IN, USA) and etesevimab (LY-CoV016 and LY3832479) (Eli Lily and Company, USA) REGN-COV2, a combination of casirivimab (REGN10933) and imdevimab (REGN10987) (Regeneron Pharmaceuticals, Tarry Town, NY, USA), and regdanvimab (CT-P59) (Celltrion, Yeonsu, Incheon, Korea) were developed and under evaluation in clinical trials. This article is an update to the previous guideline on treatment of patients with COVID-19, which was published by Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency in March of 2021 [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19

Kim

Huh

et al. 2021

Infect Chemother

Self Cite

View full text Add to dashboard Cite

Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.

show abstract

Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

Cited by 24 publications

References 177 publications

Impact of prior vaccination on clinical outcomes of patients with COVID-19

Impact of prior vaccination on clinical outcomes of patients with COVID-19

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study

Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19

Contact Info

Product

Resources

About